Novo Nordisk’s new Wegovy pill hit the market this week. The Danish drug maker, best known for GLP-1 injections like Ozempic and Wegovy, is now the first company to manufacture and receive FDA approval for an oral GLP-1 pill for weight management.

When people who are overweight and obese stopped taking their weight-loss medications they regained weight faster than those who stopped a diet or exercise program, a new review of studies finds.

And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide mesylate -- already used to treat prostate cancer -- suppressed serum luteinizing hormone concentrations in children with central precocious puberty within 24 weeks.

It’s the latest move in the race by drug companies to corner more of the highly lucrative obesity drug market.

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to their original size after around 1.

Ro Co-Founder and CEO Zach Reitano joins 'Fast Money' to talk the launch of Wegovy's oral GLP-1 offering, demand for the pill, and its partnership with Novo Nordisk to distribute the medication.

The first GLP-1 pill for obesity, semaglutide (Wegovy) tablets from drugmaker Novo Nordisk, launched in the U.S. ( CNBC) Moderna announced global regulatory submissions for its investigational seasonal influenza vaccine, an mRNA vaccine -- for adults 50 and older.

Market Domination host Josh Lipton outlines three of the top stories investors are watching on Monday: Novo Nordisk's (NVO) launching its GLP-1 pill, bitcoin's (BTC-USD) bullish start to 2026, and Qualcomm's (QCOM) CES announcements.